Background— Prognosis of ischemic cardiomyopathy still remains poor because of the lack
of effective treatments. To develop a noninvasive therapy for the disorder, we examined the …

Pulmonary arterial hypertension (PAH) is a deadly disease in which vasoconstriction and
vascular remodeling both lead to a progressive increase in pulmonary vascular resistance. …

Background— The plexiform lesion is the hallmark of severe pulmonary arterial hypertension.
However, its genesis and hemodynamic effects are largely unknown because of the …

Primary pulmonary hypertension is a fatal disease characterized by endothelial dysfunction,
hypercontraction and proliferation of vascular smooth muscle cells (VSMCs), and migration …

Objective We have recently demonstrated that low-energy extracorporeal shock wave therapy
improves chronic myocardial ischemia in pigs and humans. In this study, we examined …

Pulmonary hypertension remained an unexplained intractable disease with poor prognosis.
In the last 2 decades, however, the diagnosis and treatment methods for this disease …

Background Treatment options for patients with chronic thromboembolic pulmonary
hypertension ineligible for pulmonary endarterectomy (inoperable CTEPH) include balloon …

Therapies that exploit RNA interference (RNAi) hold great potential for improving disease
outcomes. However, there are several challenges that limit the application of RNAi therapeutics…

Current therapy of pulmonary arterial hypertension (PAH) is inadequate. Dehydroepiandrosterone
(DHEA) effectively treats experimental pulmonary hypertension in chronically hypoxic …

We have investigated the temporal relationship between the hemodynamic and histological/morphological
progression in a rat model of pulmonary arterial hypertension that develops …